The Effect of Decreasing Amounts of Live Virus, while Antigen Content Remains Constant, on Immunogenicity of OkajMerck Varicella Vaccine

Journal of Infectious Diseases

Volumn 168, Issue 6, 1993, Pages 1356-1360

  Watson, Barbara ^a,b,c   Piercy, Sharon ^a,b,c   Soppas, Despina ^a,b,c   Browngoehl, Kevin ^a,b,c   Warner, Mark ^a,b,c   Isganitis, Kathy ^a,b,c   White, C J ^a,b,c   Kuter, Barbara ^a,b,c   Chua, Janet ^a,b,c   Starr, Stuart ^a,b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Drexel Hill Pediatrics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; VARICELLA ZOSTER VACCINE; VIRUS ANTIGEN;

ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG STORAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INCIDENCE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RASH; SEROCONVERSION; VACCINATION;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FREEZING; HERPESVIRUS 3, HUMAN; HUMAN; LYMPHOCYTE ACTIVATION; MALE; SUPPORT, NON-U.S. GOV'T; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0027429652     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/168.6.1356     Document Type: Article

References (18)

1. Preblud SR, Varicella: complications and costs, Pediatrics 1982; 70: 604-8.
2. Weller TH, Varicella and herpes zoster: a perspective and overview, J Infect Dis 1992; 166(suppl I): S1-6.
3. Weibel RE, Neff BJ, Kuter BJ, Live attenuated varicella virus vaccine, N Engl J Med 1984; 310: 1409-15.
4. Arbeter AM, Starr SE, Weibel RE, Plotkin SA, Live attenuated varicella vaccine; immunization of healthy children with Oka strain, J Pediatr 1982; 100: 886-93.
5. Arbeter AM, Starr SE, Plotkin SA, Varicella vaccine studies in healthy children and adults, Pediatrics 1986; 78(suppl): 748-56.
6. Weibel RE, Kuter BJ, Neff BJ, Live Oka/Merck varicella vaccine in healthy children, JAMA 1985; 254: 2453-9.
7. Arbeter AM, Starr SE, Preblud SR, Varicella vaccine trials in healthy children: a summary of comparative and follow-up studies, Am J Dis Child 1984; 138: 434-8.
8. Johnson C, Rome LP, Stancin T, Kumar ML, Humoral immunity and clinical reinfections following varicella vaccine in healthy children, Pediatrics 1989; 84: 418-21.
9. Brunnell PA, Novelli VM, Lipton SV, Pollock B, Combined vaccine against measles, mumps, rubella, and varicella vaccine, Pediatrics 1988; 81: 779-84.
10. Gershon AA, Steinberg SP, Persistence ofimmunity to varicella in children with leukemia immunized with live attenuated varicella vaccine, N Engl J Med 1989; 320: 829-97.
11. White CJ, Kuter BJ, Hildebrand CS, Varicella vaccine (Varivax) in healthy children and adolescents: results from clinical trials, 1987 to 1989, Pediatrics 1991; 87: 604-10.
12. Kuter BJ, Weibel RE, Guess HA, Oka/Merck varicella vaccine in healthy children-final report of a 2-year efficacy study and 7-year follow-up, Vaccine 1991; 9: 643-7.
13. Chua JT, Piercy SA, Watson BM, Starr SE, A six-year follow-up study of varicella vaccine in healthy children and adolescents [abstract 1116], In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago), Washington, DC: American Society for Microbiology, 1991: 285.
14. Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML, Live attenuated varicella vaccine in healthy 12-24 month-old children, Pediatrics 1988; 81: 512-7.
15. Wasmuth EH, Miller WJ, A sensitive enzyme-linked immunosorbent assay (ELISA) for antibody to varicella-zoster virus (VZV) using purified VZV glycoprotein antigen, J Med Virol 1990; 32: 189-93.
16. Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW, Purification of individual varicella-zoster virus (VZV) glycoproteins gpl, gpll, and gpIII and their use in ELISA for detection of VZV glycoprotein specific antibodies, J Virol 1986; 57: 1195-7.
17. Watson BM, Jeller PM, Ellis RW, Starr SE, Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity, J Infect Dis 1990; 162: 794-9.
18. Bergen RE, Diaz PS, Arvin AA, The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content, J Infect Dis 1990; 162: 1049-54.